Clinical Trials
599 trialsCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
TARLATEM
Centre Leon Berard
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
Ohio State University Comprehensive Cancer Center
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
National Institutes of Health Clinical Center (CC)
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
St. Jude Children's Research Hospital
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
A Study of Mirdametinib in People With Central Nervous System Tumors
Memorial Sloan Kettering Cancer Center
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
Short Course Radiotherapy
Abramson Cancer Center at Penn Medicine
PPROSPERITIT
Masaryk University
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
EMD Serono
KinLET
ITM Solucin GmbH
JACOB
Children's National Research Institute
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
LIBRETTO-001
Eli Lilly and Company
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Massachusetts General Hospital
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
ReRT
The New York Proton Center
ELECTRA
Stemline Therapeutics, Inc.
STARTRK-NG
Hoffmann-La Roche
PNOC023
University of California, San Francisco
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
OHSU Knight Cancer Institute
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FUS Etoposide for DMG
Columbia University
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Alliance for Clinical Trials in Oncology
TECAP
Centre Hospitalier Universitaire de la Réunion
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Neonc Technologies, Inc.
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation